Journal of Gynecologic Oncology

Korean Society of Gynecologic Oncology (대한부인종양학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic impact of epithelial cell adhesion molecule in ovarian cancer patients

  • Lee, Maria (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
  • Published : 2014.10.31
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:417-23. https://doi.org/10.1038/sj.bjc.6603494
  2. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2012;38:68-75. https://doi.org/10.1016/j.ctrv.2011.04.002
  3. Woopen H, Pietzner K, Richter R, Fotopoulou C, Joens T, Braicu EI, et al. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. J Gynecol Oncol 2014;25:221-8. https://doi.org/10.3802/jgo.2014.25.3.221
  4. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion moleculespecific immunotherapy. Int J Gynecol Cancer 2009;19:860-6. https://doi.org/10.1111/IGC.0b013e3181a8331f
  5. Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006;103:483-8. https://doi.org/10.1016/j.ygyno.2006.03.035
  6. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004;86:207-13. https://doi.org/10.1023/B:BREA.0000036787.59816.01
  7. Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, Fong D, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 2004;10:3131-6. https://doi.org/10.1158/1078-0432.CCR-03-0528
  8. Went P, Dirnhofer S, Salvisberg T, Amin MB, Lim SD, Diener PA, et al. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol 2005;29:83-8. https://doi.org/10.1097/01.pas.0000.146028.70868.7a
  9. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006;94:128-35. https://doi.org/10.1038/sj.bjc.6602924
  10. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127:2209-21. https://doi.org/10.1002/ijc.25423
  11. Ott MG, Marme F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 2012;130:2195-203. https://doi.org/10.1002/ijc.26258
  12. Gutzmer R, Li W, Sutterwala S, Lemos MP, Elizalde JI, Urtishak SL, et al. A tumor-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells. J Immunol 2004;173:1023-32. https://doi.org/10.4049/jimmunol.173.2.1023

Cited by

  1. NDRG2 Expression Decreases Tumor-Induced Osteoclast Differentiation by Down-regulating ICAM1 in Breast Cancer Cells vol.24, pp.1, 2014, https://doi.org/10.4062/biomolther.2015.105
  2. Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer vol.21, pp.1, 2021, https://doi.org/10.1186/s12885-021-07928-z